Anavex Life Sciences Corp (AVXL)

[falconer66a]

Made First 2019 Buy

Checked in this morning, saw both the new Scientific Advisory Board Member and the sharply ascending AVXL price. Had some funds sitting in my Schwab account; bought a few dozen. Have a nice paper gain.

I first wondered what created all of the buy-in interest. Then saw the addition of the new guy on the Anavex SAB. I’m a biologist (retired biology teacher; now a researcher with an Ohio university research foundation on a really significant new biotechnology, not related to medical technology, however).

Clear to me guys like Dr. Kaufman don’t align themselves with start-up new biotechs unless they are certain that their participation in the company’s Scientific Advisory Board (SAB) wouldn’t in any way diminish or compromise their otherwise sterling record.

No doubt, before Kaufman signed on with Anavex he scrutinized all of the back of the lab data and information Anavex has about their sigma-1 receptor agonists. With an understanding of those data, Dr. Kaufman signed on. He knows more about the science and prospects of Anavex Life Sciences Corp than any of us outsiders. He determined that his new position with Anavex is not a career risk; rather, an opportunity.

Understanding all of that, I made my AVXL purchase this morning. Will be holding until 2023, at least.

Fine way to start the Anavex 2019 year, for both Dr. Kaufman and those of us who have taken new 2019 AVXL positions.